Navigation Links
VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
Date:5/4/2008

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN.OB), a biopharmaceutical company, announced today it has completed the sale of all assets and rights related to its recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology to Emergent BioSolutions, Inc. Under the terms of the transaction, Emergent BioSolutions paid VaxGen $2 million upon execution of the definitive agreement and may be obligated to pay up to an additional $8 million in milestone payments, plus specified percentages of future net sales.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

"We have marketed our anthrax vaccine candidate and related technology very broadly over the last 12 months," said James P. Panek, VaxGen President and CEO. "In Emergent, we believe we have identified a partner whose expertise in the field and track record in contracting with government agencies maximizes the chances of returns for our shareholders."

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the potential receipt of milestone payments and specified percentages of future net sales from Emergent BioSolutions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Additional information concerning these and other r
'/>"/>

SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. VaxGen and Raven Terminate Merger Agreement
2. VaxGen Issues Rebuttal to MedCap Letter
3. VaxGen Common Stock Now Quoted on OTC Bulletin Board
4. VaxGen Reports Financial Update
5. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
6. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
7. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
8. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
9. VaxGen Addresses MPM Claims in Letter to Stockholders
10. VaxGen Files Last Outstanding Periodic Report With SEC
11. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...recently announced that Dr. Dominique Hebrault wil...ss Analytical Technology (PAT) in Green Chemistry ... , (PRWEB) November 20, 20...echnology (PAT) in Green Chemistry and Green Engin...Technology (PAT) case studies will be presented on...
(Date:11/19/2009)...irstCall/ -- Omeros Corporation (Nasdaq: OMER ) t... third quarter ended September 30, 2009. For the t...ted a net loss of $3.9 million, or $1.34 per share....54 per share, for the same period in 2008. For th...y reported a net loss of $15.5 million, or $5.29 p...
(Date:11/19/2009)...FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), an...r to its shareholders, discussing the Company,s ac...ceuticals Holdings, Inc. (CHBP), an integrated bio...blic of China. The merger gives NeoStem a controll... Ltd., CHBP,s primary operating subsidiary and a p...
(Date:11/19/2009)...ber 19 MONITORING FORCE GmbH,annou...libanserin in the,indication treatment-relevant le...or orphan drug status designation with the Europea...esia is a complication of the mainstay,treatment i...e of those,affected, since it may be disabling for...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
..., Wis . - Online retailers that want to access the...com have no more barriers following its decision ...to an executive with the Madison-based shopping se...chant services for Jellyfish, said the company wil...echnology in combination with its cost-per-action...
... a good infrastructure has always been important t... a state. The infrastructure has traditionally bee...air as well as highways, water, and power (electri...t also include network infrastructure and the abil...ally. , ,Just as you would not locate your company...
...w big a software project was, and we will often he...have units of time. How big was another 11,000-hou...software? Or a third 11,000-hour project that prod...at was extremely profitable? There,s an intuitive ...unce of software, we,re left with hand waving. , ,...
Other Biology Technology:Jellyfish partners for sales tracking technology 2States need to be more "connectivity conscious" 2States need to be more "connectivity conscious" 3States need to be more "connectivity conscious" 4Defining the X-factor: What is an ounce of software worth? 2Defining the X-factor: What is an ounce of software worth? 3Defining the X-factor: What is an ounce of software worth? 4
(Date:11/20/2009)...rchers report that a class of heart medications ca... effect on the heart, depending on their molecular...rnal Circulation Research , found that beta-block... on the heart muscle offer the most benefit to car...ta-receptors can actually undermine the structure ...
(Date:11/19/2009)...ealing the genetic instructions inside corn, one o...one of the most complex sequences of DNA ever anal...ist David Schwartz, who was one of more than 100 a... "The maize genome is a true maze full of confus...-be sequencers for years," says Schwartz. , Publ...
(Date:11/19/2009)...ty in maize, also known as corn, researchers acros...t should pave the way to significant improvements ...nimal feed and fiber around the world. , The new...ype map, charts genetic diversity and recombinatio...he research team, led by U.S. Department of Agricu...
Breaking Biology News(10 mins):Carvedilol shown to have unique characteristics among beta blockers 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza 28TM 29 28Cethromycin 29 in Community Acquired Pneumonia 13312 1Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza 28TM 29 28Cethromycin 29 in Community Acquired Pneumonia 13312 2Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza 28TM 29 28Cethromycin 29 in Community Acquired Pneumonia 13312 3Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza 28TM 29 28Cethromycin 29 in Community Acquired Pneumonia 13312 4Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza 28TM 29 28Cethromycin 29 in Community Acquired Pneumonia 13312 5In Letter to Congress NORD Urges Action on Healthcare Reform 53373 1In Letter to Congress NORD Urges Action on Healthcare Reform 53373 2In Letter to Congress NORD Urges Action on Healthcare Reform 53373 3Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 53371 1Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 53371 2Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 53371 3
...very made by researchers at Wake Forest University...xplain how some people without a genetic predispos...a study published this month in the Journal of Ne...h.D., a professor of neurobiology and anatomy, and...dy known to predispose people who inherit an activ...
...ial roles in our daily lives. The chemical senses ... the presence of potentially harmful situations or...ed food. Flavors and fragrances are also important...al products we use. The pleasures derived from eat...ands of Americans experience loss of smell or tast...
...ears after the AIDS epidemic spawned a worldwide s...mmunodeficiency virus (HIV), progress in the field...son? According to new findings from a team of rese...y (Caltech), it,s at least partly due to the fact ...t have a long enough reach to effectively neutrali...
Other Biology News:Researchers discover that gene switches on during development of epilepsy 2Researchers discover that gene switches on during development of epilepsy 3New findings in taste and smell 2Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection 2Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection 3
Mouse Anti-JAB1 (Mid) Monoclonal Antibody, Clone 3F10B10 from Invitrogen
HISTOMOUNT SOLUTION from Invitrogen
3' RACE Adapter Primer from Invitrogen
Cholesterol Fluorometric (Red) Assay Kit, Amplex Red from Molecular Probes (Invitrogen)
Biology Products: